NEJM Phase 3 Study Shows Ustekinumab Helps People Suffering With Ulcerative Colitis
November 01, 2019
November 01, 2019
MIAMI, Florida, Nov. 1 [TNSmedicalresearch-New England Journal of Medicine]-- The University of Miami's Miller School of Medicine issued the following news:
The biologic drug ustekinumab effectively induced and maintained remission in patients with moderate to severe ulcerative colitis, according to a phase 3 study published in the prestigious New England Journal of Medicine (NEJM).
The FDA approved ustekinumab, marketed as Stelara, for the treatment of adult patients w . . .
The biologic drug ustekinumab effectively induced and maintained remission in patients with moderate to severe ulcerative colitis, according to a phase 3 study published in the prestigious New England Journal of Medicine (NEJM).
The FDA approved ustekinumab, marketed as Stelara, for the treatment of adult patients w . . .